Ashraf Elbahrawy

Prof. Ashraf Elbahrawy


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2023 in Viruses
Verified
Journal Article
Open access
PDF file
AEAshraf Elbahrawy
Ashraf Elbahrawy
HAHassan Atalla
Hassan Atalla
MAMohamed Alboraie
Mohamed Alboraie
ِAِAhmed Alwassief
ِAhmed Alwassief
AMAli Madian
Ali Madian
Hussein Hassan AlyHussein Hassan Aly
Hussein Hassan Aly
Vaccination has been confirmed to be the safest and, sometimes, the only tool of defense against threats from infectious diseases. The successful history of vaccination is evident in the control of serious viral infections, such as smallpox and polio. Viruses that infect human livers are known as hepatitis viruses and are classified into five major types from A to E, alphabetically. Although infection with hepatitis A virus (HAV) is known to be self-resolving after rest and symptomatic treatment, there were 7134 deaths from HAV worldwide in 2016. In 2019, hepatitis B virus (HBV) and hepatitis C virus (HCV) resulted in an estimated 820,000 and 290,000 deaths, respectively. Hepatitis delta virus (HDV) is a satellite virus that depends on HBV for producing its infectious particles in order to spread. The combination of HDV and HBV infection is considered the most severe form of chronic viral hepatitis. Hepatitis E virus (HEV) is another orally transmitted virus, common in low- and middle-income countries. In 2015, it caused 44,000 deaths worldwide. Safe and effective vaccines are already available to prevent hepatitis A and B. Here, we review the recent advances in protective vaccines against the five major hepatitis viruses.

23 February 2012 in Hemodialysis International
Verified
Journal Article
Closed access
PDF file
AEAssem El‐Sherif
Assem El‐Sherif
AEAshraf Elbahrawy
Ashraf Elbahrawy
AAAtef Aboelfotoh
Atef Aboelfotoh
MAMagdy Abdelkarim
Magdy Abdelkarim
AMAbdel‐Gawad Saied Mohammad
Abdel‐Gawad Saied Mohammad
KAKouka Saadeldin Abdelwahab
Kouka Saadeldin Abdelwahab

7 March 2009 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
AEAssem El-Sherif
Assem El-Sherif
MAMohamed Abou-Shady
Mohamed Abou-Shady
HAHany Abou-Zeid
Hany Abou-Zeid
AEAhmed Elwassief
Ahmed Elwassief
AEAshraf Elbahrawy
Ashraf Elbahrawy
AHAbdel-Moneim Hosney
Abdel-Moneim Hosney

19 September 2013 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
PDF file
HEHeba Elrashidy
Heba Elrashidy
AEAshraf Elbahrawy
Ashraf Elbahrawy
GEGamal El-Didamony
Gamal El-Didamony
NGNilly M George
Nilly M George
ِAِAhmed Alwassief
ِAhmed Alwassief
MAMohamed Ali Abdelbasseer
Mohamed Ali Abdelbasseer
Background: The remarkable effectiveness of universal infantile hepatitis B (HB) vaccination is well documented in many countries. Nevertheless, the influence of insulin-dependent diabetes mellitus (IDDM) on the sero-protective level of antibody to hepatitis B surface antigen (anti-HBs) after HB vaccination has not been investigated in Egyptian children. The aim of this study was to investigate long-term anti-HBs sero-protective levels after infantile HB vaccination in Egyptian IDDM children. Results: The mean age of the healthy children was 10.86 ± 1.21 y (range, 5.5–15 y); 49 (45.8%) were boys and 58 (54.2%) were girls. The mean age of the IDDM children was 10.29 ± 3.04 y (range, 4–17 y); 32 (50.8%) were boys and 31 (49.2%) were girls. There were no significant differences between the healthy and IDDM children with respect to age and sex (p > 0.05). Among the 107 healthy children, 43 (40%) did not have a protective anti-HBs level (anti-HBs < 10 IU/L) and 64 (60%) had a protective level (anti-HBs ≥ 10 IU/L). In contrast, among the IDDM children, 44 (69.8%) and 19 (30.2%) did not and did have protective anti-HBs levels, respectively. This difference in anti-HBs concentration between healthy and diabetic children was highly significant (p < 0.001). None of the vaccinated healthy or IDDM children was reactive to HBsAg or total anti-HBc. Patients and Methods: A total of 170 children (81 boys, 89 girls) who had been routinely vaccinated against HB were included. Their mean age was 10 ± 2.1 y. The enrolled children were divided into healthy (n = 107) and IDDM (n = 63) cohorts. Body Mass Index and levels of hepatitis B surface antigen (HBsAg), total antibody to hepatitis B core antigen (anti-HBc), and anti-HBs were evaluated in all children. In addition, the duration of diabetes mellitus (DM) and levels of glycated hemoglobin (HbA1c) were measured in IDDM children. Conclusion: Our results are alarming. It appears that the majority of Egyptian diabetic children vaccinated against HB may not have sufficient anti-HBs levels to protect them from HB. Moreover, this study emphasizes the need for a population-based strategy for the management of patients without an anti-HBs protective level after HB vaccination and justifies the need to elucidate the heritability of those children.

1 January 2015 in World Journal of Hepatology
Verified
Journal Article
Open access
AEAshraf Elbahrawy
Ashraf Elbahrawy
AAAlshimaa Alaboudy
Alshimaa Alaboudy
WMWalid El Moghazy
Walid El Moghazy
AEAhmed Elwassief
Ahmed Elwassief
AAAhmed Alashker
Ahmed Alashker
AAAbdallah Mahmoud Abdallah
Abdallah Mahmoud Abdallah
The emerging evidence of the potentially clinical importance of occult hepatitis B virus (HBV) infection (OBI) increases the interest in this topic. OBI may impact in several clinical contexts, which include the possible transmission of the infection, the contribution to liver disease progression, the development of hepatocellular carcinoma, and the risk of reactivation. There are several articles that have published on OBI in Egyptian populations. A review of MEDLINE database was undertaken for relevant articles to clarify the epidemiology of OBI in Egypt. HBV genotype D is the only detectable genotype among Egyptian OBI patients. Higher rates of OBI reported among Egyptian chronic HCV, hemodialysis, children with malignant disorders, and cryptogenic liver disease patients. There is an evidence of OBI reactivation after treatment with chemotherapy. The available data suggested that screening for OBI must be a routine practice in these groups of patients. Further studies needed for better understand of the epidemiology of OBI among Egyptian young generations after the era of hepatitis B vaccination.

17 January 2020 in Gastrointestinal Tumors
Verified
Journal Article
Open access
PDF file
MFMohammed El Fayoumie
Mohammed El Fayoumie
MAMahmoud Abdelhady
Mahmoud Abdelhady
AGAhmed Gawish
Ahmed Gawish
UHUsama Hantour
Usama Hantour
IAIsmail Abdelkhaleek
Ismail Abdelkhaleek
AEAshraf Elbahrawy
Ashraf Elbahrawy
Introduction: The impact of direct antiviral agents (DAAs) on the development of hepatocellular carcinoma (HCC) is controversial. One important aspect of this controversy is the changing pattern of HCC. Objective: In this study, we attempted to assess the changes in the pattern of HCC after treatment with DAAs. Methods: A total of 51 HCC patients after DAA treatment and 54 HCC patients without DAA treatment were included. The diagnosis of HCC was based on typical dynamic CT and/or MRI criteria in both groups. Liver status was assessed by means of the fibrosis 4 index (Fib-4), Child-Pugh classification, and model for end-stage liver disease (MELD). HCC infiltrative pattern, portal vein thrombosis (PVT), local and distant metastases, and α-fetoprotein (AFP) level were compared in the 2 groups. The staging of HCC and treatment decisions were made in both groups following the Milan criteria, Barcelona Clinic Liver Cancer staging, tumor-node-metastasis staging, and Cancer of the Liver Italian Program categorization. Results: The mean age of the HCC patients after DAA treatment (59.1± 7.4 years) was older than that of the HCC patients without DAA treatment. There was no significant difference between groups regarding sex distribution. The mean Fib-4 score (4.84 ± 3.53) was significantly lower in HCC patients after DAA treatment than in those without DAA treatment. The frequency of the infiltrative HCC pattern, PVT, and regional lymph node metastasis was significantly higher in HCC patients after DAA treatment than in those without DAA treatment (p ≤ 0.05); mean AFP level (5,085.2 ± 11,883.2 ng/mL) was also significantly higher. HCC patients after DAA treatment had significantly advanced stages and limited treatment options (p ≤ 0.05). Conclusion: The changing HCC pattern after DAA treatment may suggest the need for new HCC staging and treatment protocols.